Reduce PFE exposure 25-33% via staged exits in $28.00-$28.50 zone; hold residual with stop at $25.50
Underweight rating with 25-33% trim is the calibrated response: (1) trim zone $28.00-$28.50 is still executable on relief bounces while full Sell cannot be mechanically executed at current $27.72 without chasing; (2) bearish technicals (MACD cross, RSI rollover from 70s, price below 10-EMA/VWMA) match patterns where Hold has produced -1.1% to -2.2% alpha drag per 9/10 binding reflection; (3) dividend funded (TTM FCF coverage 1.27x, $11.7B cash) and 200 SMA intact at $25.50 reject full liquidation; (4) 25-33% trim is large enough to neutralize beta drag while preserving yield carry and post-Q3 breakout optionality.
| Position | Action |
|---|---|
| Any relief bounce to $28.00-$28.25 | Sell initial 15-20% of position |
| Price reaches $28.50-$28.80 | Sell reserve 10-15% of position |
| Price below $28.00 | Avoid selling unless broader tape turns risk-off |
| Close below $24.00 | Escalate to full Sell |
| Post-trim capital redirection | Allocate 50% to JNJ/ABBV defensives; 50% to cash/short-duration Treasuries |
Pfizer is a deeply undervalued defensive yield play with 6.22% dividend yield exceeding Treasuries by 120bps, a forward P/E of just 9.6x, and a macro tailwind from hawkish Fed regime that favors low-beta cash-flow-rich names—positioned for institutional accumulation ahead of Q3 confirmation and pipeline catalysts.
| Indicator | Value | Signal |
|---|---|---|
| close_10_ema | 28.00 | neutral |
| close_50_sma | 26.14 | bullish |
| close_200_sma | 25.53 | bullish |
| rsi | 53.42 | neutral |
| macd | 0.48 | bullish |
| macd_signal | 0.67 | bearish |
| macd_histogram | -0.19 | bearish |
| atr | 0.56 | neutral |
| boll_ub | 29.18 | neutral |
| boll_mid | 28.00 | neutral |
| boll_lb | 26.83 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Price holds $26.80-$27.40 support with confirmed catalyst
Then: Reassess for post-Q3 re-entry
Forward P/E of 9.6x represents genuine value as the trailing P/E of 36.5x is artificially inflated by ~$10 billion in non-cash impairment charges (Q4'25: $5.4B; Q2'26: $4.4B), with normalized EPS of $2.50–$3.00 vs forward consensus of $2.90.
EV: +8% (to $30.00+) · concedes: Patent cliff on Eliquis, Ibrance, and Xtandi in 2026-2028 is real and requires Seegen backfill; COVID revenue structurally decaying from $101B (2022) to $63B (2025); Q2'26 FCF of $12.5B barely covers $9.8B dividend at 93% coverage; MACD histogram did flip negative at -0.19; trailing P/E of 36.5x is technically accurate though artificially inflated by non-cash charges
PFE is a balance sheet being slowly unwound — the 6.22% dividend yield is a warning sign of distressed earnings, not a reward, and the stock faces compounding headwinds from patent cliffs, impairments, negative revenue growth, and macro pressures that make the bull's coiled-spring thesis a falling knife in slow motion.
· concedes: FY2024 OCF was $12.7B and FY2025 OCF was $11.7B — covering the $9.7-9.8B dividend on TTM basis; Operating income is steady at $3.5-4.3B/quarter (though consumed by non-operating items); Cost-cut program is real (though one-time tailwind); Q2 beat estimates (though marginal, driven by non-cash adjustments)
→ vs neutral: Risk-reward at 9.6x forward earnings with 6% yield and 0.3 beta is not balanced—it is asymmetric to upside with downside floor; waiting for Q3 confirmation causes underperformance by buying breakouts instead of positioning before confirmation; 'hold for income' misses the multiple reversion from 9.6x to 14x that occurs when impairment noise clears
→ vs conservative: Eliquis patent cliff is multi-year known event with built-in re-rating setup, not binary outcome; net debt-to-EBITDA 2.45x and debt-to-equity 74% manageable for major pharma with this cash flow; Seegen integration two years in with deal validation materializing now; COVID revenue decay is known declining headwind, not fresh risk; comparing to 2022 peak $101B wrong comparison—the stabilized $15B quarterly base is the right baseline
| vwma | ~28.23 | neutral |
Support: 26.83 · 26.14 · 25.53 | Resistance: 28 · 29.09 · 29.18
PFE exhibits a bullish long-term structure with price +8.6% above the 200 SMA (25.53) and +6.0% above the 50 SMA (26.14), though short-term momentum is cooling as price sits just below the 10 EMA (28.00) for the first sustained period since early August. The MACD has crossed bearish with a negative histogram (-0.19) but remains in positive territory, suggesting profit-taking rather than structural reversal. RSI at 53.42 indicates neutral conditions without overbought/oversold extremes. The pullback from 29.09 (Sep 2) is occurring on declining volume (~25.5M vs 35-45M typical), which is technically constructive. The critical support level is 26.83 (Bollinger lower band), with 27.40 as an intermediate shelf; resistance sits at 28.00 (10 EMA/Bollinger midline) and 29.18 (Bollinger upper band). The pattern resembles a bull-flag continuation within a larger uptrend, not a topping formation. Rating: HOLD — accumulate weakness toward 26.83-27.40 only with confirmed daily close above 28.00; avoid initiating fresh longs at current levels until MACD histogram re-firms positive or price reclaims the 10 EMA on volume.
Market Cap
$157.99B
Current Price
~$27.72
52-Week Range
$23.58 – $29.21
Beta
0.30
Dividend Yield
6.22%
P/E (TTM)
36.5x
Forward P/E
9.6x
Forward EPS
$2.90
PEG Ratio
2.72
Price/Book
1.85x
EV/EBITDA (TTM)
~8.7x
FCF Yield (TTM)
~7.9%
Operating Margin
27.9%
Return on Equity
5.0%
Return on Assets
5.8%
Debt-to-Equity
74.3%
Current Ratio
1.27
Book Value per Share
$14.95
Tangible Book Value
Negative ~($33B)
Net Debt / TTM EBITDA
~2.45x
Revenue (FY 2025)
$62.58B
Gross Profit (FY 2025)
$46.51B
Operating Income (FY 2025)
$17.41B
Net Income (FY 2025)
$7.77B
Diluted EPS (FY 2025)
$1.36
Normalized EBITDA (FY 2025)
$25.75B
Cost of Revenue (FY 2025)
$16.07B
R&D (FY 2025)
$10.44B
SG&A (FY 2025)
$13.79B
D&A (FY 2025)
$6.59B
Diluted EPS (TTM)
$0.76
Revenue (TTM)
$63.70B
EBITDA (TTM)
$25.38B
Operating Cash Flow (TTM)
~$13.5B
Free Cash Flow (FY 2025)
$9.08B
Free Cash Flow (TTM)
$12.49B
Dividends Paid (FY 2025)
$9.77B
Total Debt
$63.19B
Net Debt
$62.22B
Goodwill & Intangibles
$118.47B
Stockholders' Equity
$85.19B
Cash & ST Investments
$11.70B
Working Capital
$8.71B
Annual Dividends
$9.77B
Net Debt (2022 pre-Seagen)
$34.4B
Impairment Charges (Q4'25)
$5.4B
Impairment Charges (Q2'26)
$4.4B
Cumulative Impairments (6 quarters)
$10B+
Normalized EPS (estimated)
$2.50-$3.00
Revenue Peak (2022 COVID)
$101.18B
Strengths
Concerns
Pfizer presents a distorted valuation picture with trailing metrics (P/E 36.5x, ROE 5.0%) severely impaired by ~$10B+ in non-cash goodwill write-downs over 6 quarters, while normalized EPS of $2.50-$3.00 implies a normalized P/E of 9-10x—making it cheap on an earnings recovery basis. The 6.22% dividend yield is the primary attraction but sits on thin FCF coverage (~$12.5B TTM FCF vs. $9.8B annual dividend), creating sustainability risk if earnings deteriorate. Key risks include the Eliquis patent cliff (2026-2028) threatening ~$12-13B in annual revenue and the company's elevated net debt position of $62.2B, while the Seagen oncology acquisition and stable 27.9% operating margins provide modest growth prospects into 2027-2028.
Macro: Hawkish Fed regime: prediction markets show 94% probability of no Fed rate cuts in 2026 (up 0.8pp in one week), with a rate hike now "close to a lock" per IBD; US recession odds at just 7% for end-2026 (up 0.5pp); UK and Japan recession odds at 5% and 6% respectively (both falling). 10-year Treasury holding just below 5% on firm inflation data per WSJ.